Understanding the Terminology: Invasive Pulmonary Aspergillosis vs. Invasive Aspergillosis
Invasive pulmonary aspergillosis (IPA) is not a separate disease from invasive aspergillosis (IA)—rather, IPA is the most common anatomical manifestation of IA, specifically affecting the lungs. 1
The Relationship Between Terms
Invasive aspergillosis (IA) is the umbrella term that encompasses all forms of tissue-invasive Aspergillus infection, regardless of anatomical location. IPA specifically refers to IA occurring in the pulmonary system. 1, 2
According to the 2016 Taiwan guidelines and IDSA guidelines, IA can manifest in multiple anatomical sites 1, 2:
Anatomical Forms of Invasive Aspergillosis:
- Invasive pulmonary aspergillosis (IPA) - lungs (most common, ~70-90% of cases)
- Invasive sinonasal aspergillosis - sinuses
- Tracheobronchial aspergillosis - airways
- CNS aspergillosis - brain and spinal cord
- Aspergillus endocarditis - heart valves
- Aspergillus osteomyelitis - bones
- Cutaneous aspergillosis - skin and soft tissue
- Aspergillus peritonitis - peritoneum
Key Clinical Distinctions
When You're Dealing with IPA Specifically:
IPA presents with respiratory-focused manifestations 3, 4:
- Fever, cough, dyspnea, chest pain, hemoptysis
- CT findings: nodules with halo sign, air crescent sign, cavitation, consolidation, ground-glass opacities 5
- Diagnosis relies on respiratory samples (BAL, sputum) for galactomannan, culture, and PCR 6
- Treatment duration: minimum 6-12 weeks 1
- Surgical intervention indicated for lesions near great vessels, chest wall invasion, or persistent hemoptysis 1
When You're Dealing with Extrapulmonary IA:
Different anatomical sites require site-specific management approaches 1, 2:
- CNS aspergillosis: Highest mortality among all IA forms; requires surgical resection when feasible; must monitor drug interactions with anticonvulsants 1, 2
- Endocarditis: Requires early surgical intervention plus lifelong antifungal therapy post-operatively 1
- Sinonasal: Must consider mucormycosis in differential; surgical debridement recommended 1
Common Clinical Pitfall
The critical error is assuming "invasive aspergillosis" without the "pulmonary" qualifier means something different from lung involvement. In clinical practice and literature, when clinicians say "invasive aspergillosis" without specifying location, they are typically referring to IPA because it represents the vast majority of cases (70-90%) 7, 8. However, proper documentation should specify the anatomical site.
Practical Algorithm for Classification:
Confirm invasive disease (not colonization or allergic disease):
Identify anatomical site(s):
- Respiratory symptoms + lung imaging abnormalities = IPA
- Neurological symptoms + brain lesions = CNS aspergillosis
- Multiple organ involvement = disseminated IA
Document as: "Invasive aspergillosis, [specific anatomical site]" or simply "Invasive pulmonary aspergillosis" when lungs are involved
Treatment Implications
The distinction matters because treatment strategies vary by anatomical site 1, 2:
- All forms: Voriconazole remains first-line (or liposomal amphotericin B as alternative)
- IPA: May not require surgery unless specific indications present
- CNS/Endocarditis: Surgery often mandatory for cure
- Sinonasal: Surgical debridement strongly recommended
The underlying principle: IPA is a subset of IA, not a separate entity. When you diagnose IPA, you are diagnosing invasive aspergillosis that happens to be located in the lungs.